SCHEMBL31710828

SCHEMBL31710828

Fc1ccc(OCC2COC2)c(Br)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.49
HTR2A P28223 2/20 0.44
HTR2C P28335 2/20 0.44
HTR2B P41595 2/20 0.44
RAB9A P51151 2/20 0.39
MAPT P10636 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
NTRK1 P04629 1/20 0.37
NTRK3 Q16288 1/20 0.37
NTRK2 Q16620 1/20 0.37
GRM5 P41594 1/20 0.36
ALDH1A1 P00352 2/20 0.36
RBP4 P02753 1/20 0.35
FFAR1 O14842 1/20 0.35
LMNA P02545 1/20 0.34
HTT P42858 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MGLL Q99685 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL985592 0.85 HTR2A (0.54) PKMHTR2AHTR2CHTR2BRAB9A
SCHEMBL31710999 0.85 HTR2A (0.48) PKMHTR2AHTR2CHTR2BRAB9A
SCHEMBL9774749 0.83 ALDH1A1 (0.50) PKMHTR2AHTR2CHTR2BRAB9A
SCHEMBL18907926 0.81 ALDH1A1 (0.45) HTR2AHTR2CHTR2BNTRK1NTRK3
SCHEMBL21949867 0.81 PKM (0.49) PKMHTR2AHTR2CHTR2BRAB9A
SCHEMBL17111325 0.81 DRD4 (0.46) HTR2AHTR2CHTR2BFFAR1
SCHEMBL18907906 0.78 HTR2A (0.41) HTR2AHTR2CHTR2BNTRK1NTRK3
SCHEMBL20497371 0.76 PKM (0.50) PKMHTR2AHTR2CHTR2BRAB9A
SCHEMBL20497372 0.76 PKM (0.50) PKMHTR2AHTR2CHTR2BRAB9A
SCHEMBL23230162 0.74 SLC6A2 (0.63) HTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326772-A1 MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER KYORIN SEIYAKU KK (JP) 2025-10-23 US disclosed
US-20250326773-A1 MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER KYORIN SEIYAKU KK (JP) 2025-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326772-A1 MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER MRGPRX2, MRGPRX1, MRGPRX4 PKM 3041/4885HTR2A 733/4885HTR2C 981/4885
US-20250326773-A1 MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER MRGPRX2, MRGPRX1, MRGPRX4 PKM 3041/4885HTR2A 733/4885HTR2C 981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.